[go: up one dir, main page]

SE0101981D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0101981D0
SE0101981D0 SE0101981A SE0101981A SE0101981D0 SE 0101981 D0 SE0101981 D0 SE 0101981D0 SE 0101981 A SE0101981 A SE 0101981A SE 0101981 A SE0101981 A SE 0101981A SE 0101981 D0 SE0101981 D0 SE 0101981D0
Authority
SE
Sweden
Prior art keywords
ethoxy
pharmaceutical combination
phenyl
propanoic acid
methanesulfonyloxyphenyl
Prior art date
Application number
SE0101981A
Other languages
English (en)
Inventor
Peter Oehman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101981A priority Critical patent/SE0101981D0/sv
Publication of SE0101981D0 publication Critical patent/SE0101981D0/sv
Priority to BR0210129-7A priority patent/BR0210129A/pt
Priority to RU2003136156/15A priority patent/RU2003136156A/ru
Priority to EEP200300577A priority patent/EE200300577A/xx
Priority to IL15903402A priority patent/IL159034A0/xx
Priority to MXPA03011012A priority patent/MXPA03011012A/es
Priority to CZ20033233A priority patent/CZ20033233A3/cs
Priority to EP02736371A priority patent/EP1401485A1/en
Priority to JP2002592962A priority patent/JP2004532873A/ja
Priority to PCT/SE2002/001037 priority patent/WO2002096453A1/en
Priority to KR10-2003-7015636A priority patent/KR20040072027A/ko
Priority to CNA028149645A priority patent/CN1535155A/zh
Priority to CA002448637A priority patent/CA2448637A1/en
Priority to SK1471-2003A priority patent/SK14712003A3/sk
Priority to NZ529812A priority patent/NZ529812A/xx
Priority to PL02367704A priority patent/PL367704A1/xx
Priority to US10/479,707 priority patent/US20040147600A1/en
Priority to HU0400964A priority patent/HUP0400964A3/hu
Priority to NO20035236A priority patent/NO20035236D0/no
Priority to ZA200309261A priority patent/ZA200309261B/en
Priority to IS7056A priority patent/IS7056A/is
Priority to CO03112112A priority patent/CO5540383A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0101981A 2001-06-01 2001-06-01 Pharmaceutical combination SE0101981D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
HU0400964A HUP0400964A3 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl]ethoxy))phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and insulin
KR10-2003-7015636A KR20040072027A (ko) 2001-06-01 2002-05-30 (ｓ)-2-에톡시-3-[4-(2-[4-메탄술포닐옥시페닐]에톡시)페닐]프로판산 또는3-[4-[2-(4-ｔ-부톡시카르보닐아미노페닐)에톡시]페닐]-(ｓ)-2-에톡시 프로판산 및 인슐린을 포함하는 약학 조합물
CA002448637A CA2448637A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
EEP200300577A EE200300577A (et) 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja insuliini
IL15903402A IL159034A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4- (2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}- (s) -2- ethoxy propanoic acid and insulin
MXPA03011012A MXPA03011012A (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina.
CZ20033233A CZ20033233A3 (cs) 2001-06-01 2002-05-30 Farmaceutická kombinace
EP02736371A EP1401485A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin
JP2002592962A JP2004532873A (ja) 2001-06-01 2002-05-30 （Ｓ）−２−エトキシ−３−［４−（２−｛４−メタンスルホニルオキシフェニル｝エトキシ）フェニル］プロパン酸または３−｛４−［２−（４−ｔｅｒｔ−ブトキシカルボニルアミノフェニル）エトキシ］フェニル｝−（Ｓ）−２−エトキシプロパン酸のいずれかとインスリンとを含んでなる医薬組合わせ
PCT/SE2002/001037 WO2002096453A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
BR0210129-7A BR0210129A (pt) 2001-06-01 2002-05-30 Combinação farmacêutica, métodos de tratamento ou de prevenção de diabetes e de tratamento da sìndrome de resistência à insulina, kit de partes, produto combinado, e, método de produção do mesmo
CNA028149645A CN1535155A (zh) 2001-06-01 2002-05-30 一种包含(s)-2-乙氧基-3-[4-(2-{4-甲磺酰基氧基苯基}乙氧基）苯基]丙酸或3-{4-[2-（4-叔丁氧基羰基氨基苯基）乙氧基]苯基}-（s）-2-乙氧基丙酸和胰岛素的联合药物
RU2003136156/15A RU2003136156A (ru) 2001-06-01 2002-05-30 Фармацевтическая комбинация, содержащая либо (s)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]-пропионовую кислоту, либо 3-{4-[2-(4-третбутоксикарбониламинофенил)этокси]фенил}-(s)-этоксипропионовую кислоту и инсулин
SK1471-2003A SK14712003A3 (sk) 2001-06-01 2002-05-30 Farmaceutická kombinácia obsahujúca buď kyselinu (S)-2-etoxy-3- [4-(2-{4-metánsulfonyloxyfenyl}-etoxy)fenyl]propánovú, alebo kyselinu 3-{4-[2-(4-terc-butoxykarbonylaminofenyl)etoxy]fenyl}- (S)-2-etoxypropánovú a inzulín
NZ529812A NZ529812A (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (S)-2- ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(S)-2-ethoxy propanoic acid and insulin
PL02367704A PL367704A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3 4-(2- 4-methane sulfonyl oxyphenyl ethoxy)phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and insulin
US10/479,707 US20040147600A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s-2ethoxy propanoic acid and insulin
NO20035236A NO20035236D0 (no) 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3 (4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl) - (S) -2-
ZA200309261A ZA200309261B (en) 2001-06-01 2003-11-27 A pharmaceutical combination comprising either (S)-2-ethoxy-3[4-(2- {4-methane sulfonyl oxyphenyl}ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl) ethoxy]phenyl}-(S)-2-ethoxy propanoic acid and insulin.
IS7056A IS7056A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
CO03112112A CO5540383A2 (es) 2001-06-01 2003-12-23 UNA COMBINACION FARMACEUTICA QUE COMPRENDE UNO CUALQUIERA DE ACIDO (S)-2-ETOXI-3-(4-(2-(4-METANOSULFONIL OXIFENIL) ETOXI)FENIL) PROPANOICO O ACIDO 3-(4-(2-(4-TERT-BUTOXI CARBONIL-AMINOFENIL)ETOXI)FENIL)-(s)-2-ETOXI PROPANOICO E INSULINA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0101981D0 true SE0101981D0 (sv) 2001-06-01

Family

ID=20284363

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101981A SE0101981D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Country Status (22)

Country Link
US (1) US20040147600A1 (sv)
EP (1) EP1401485A1 (sv)
JP (1) JP2004532873A (sv)
KR (1) KR20040072027A (sv)
CN (1) CN1535155A (sv)
BR (1) BR0210129A (sv)
CA (1) CA2448637A1 (sv)
CO (1) CO5540383A2 (sv)
CZ (1) CZ20033233A3 (sv)
EE (1) EE200300577A (sv)
HU (1) HUP0400964A3 (sv)
IL (1) IL159034A0 (sv)
IS (1) IS7056A (sv)
MX (1) MXPA03011012A (sv)
NO (1) NO20035236D0 (sv)
NZ (1) NZ529812A (sv)
PL (1) PL367704A1 (sv)
RU (1) RU2003136156A (sv)
SE (1) SE0101981D0 (sv)
SK (1) SK14712003A3 (sv)
WO (1) WO2002096453A1 (sv)
ZA (1) ZA200309261B (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1535612B1 (en) * 2003-11-28 2006-09-13 Merck Sante Treatment for hyperuricemia
DOP2006000018A (es) * 2005-01-28 2006-07-15 Lilly Co Eli Formulaciones y regimen de dosificación para moduladores alfa de ppar
CA2723949A1 (en) * 2008-05-19 2009-11-26 Nestec S.A. Methods for reducing lipid absorption by an animal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone

Also Published As

Publication number Publication date
RU2003136156A (ru) 2005-05-20
EE200300577A (et) 2004-02-16
EP1401485A1 (en) 2004-03-31
JP2004532873A (ja) 2004-10-28
CO5540383A2 (es) 2005-07-29
US20040147600A1 (en) 2004-07-29
NO20035236D0 (no) 2003-11-25
CN1535155A (zh) 2004-10-06
CZ20033233A3 (cs) 2004-12-15
CA2448637A1 (en) 2002-12-05
NZ529812A (en) 2006-03-31
IL159034A0 (en) 2004-05-12
HUP0400964A2 (hu) 2004-08-30
HUP0400964A3 (en) 2007-11-28
KR20040072027A (ko) 2004-08-16
WO2002096453A1 (en) 2002-12-05
MXPA03011012A (es) 2004-02-27
PL367704A1 (en) 2005-03-07
SK14712003A3 (sk) 2004-08-03
IS7056A (is) 2003-11-28
ZA200309261B (en) 2005-02-28
BR0210129A (pt) 2004-06-08

Similar Documents

Publication Publication Date Title
SV2006002243A (es) "procedimiento" ref. bhc041061-sv
MX338024B (es) Derivado de dibencilamina opticamente activa y metodo para prepararla.
BR0312103A (pt) Combinações de substâncias ativas fungicidas
CR7439A (es) Pirazolilcarboxanilidas disubstituidas
EE200200284A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
RS51497B (sr) w-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
NO20013674D0 (no) Acetyleniske <alfa>-aminosyre-baserte sulfonamid- hydroksamsyre TACE-inhibitorer
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
EA200300067A1 (ru) Кристаллическая форма целекоксиба
DK1370543T3 (da) Bredspektrede 2-(substitueret amino) benzothiazol- sulfonamid-HIV-proteaseinhibitorer
EA200300927A1 (ru) Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
SE0101981D0 (sv) Pharmaceutical combination
NO20034988D0 (no) Bredspektret 2-(amino)-benzoxazolsulfonamid HIV proteasehemmere
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
SE0101982D0 (sv) Pharmaceutical combination
NO20045444L (no) Bredspektrede substituerte benzoksazolsulfonamid HIV-proteaseinhibitorer
SE0101980D0 (sv) Pharmaceutical combination
ATE482952T1 (de) Ethanolaminsalz von n-(methoxy-5-methylpyrazin-2- yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3 sulfonamid
RS52014B (sr) Nova so benzoilgvanidina
CO5630026A2 (es) Sales de amina de acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[metilsulfonil)oxi]fenoxi}etil)fenil]propanoico y su uso en medicina
ATE250600T1 (de) Optische spaltung von 1-azabicylo(2.2.2)octan-3- amin,2-(diphenylmethyl)-n-((2-methoxy-5-(1- methylethyl)phenyl)methyl)
DE50313047D1 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl-harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
DE60310896D1 (de) PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN
AR030731A1 (es) Nuevas formas de sales solidas de n-(2-(4-[2-(1-metiletoxi)fenil]-1-piperazinil]etil]-2-oxo-1-piperidinacetamida
BR0111049A (pt) Processo para a preparação de ácido 4-(4-piridinil)-benzóico, ou de um seu sal